Paper324964
Adverse reactions to rifampicin in antituberculosis regimens.
Girling DJ. J Antimicrob Chemother, 1977. Cited by 128 papers, by iCite.
Cite this record
ConductScience Library. Adverse reactions to rifampicin in antituberculosis regimens. Papers, record 324964. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/324964
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Rifampin | Major topic |
| Tuberculosis, Pulmonary | Major topic |
| Acute Kidney Injury | |
| Anemia, Hemolytic | |
| Digestive System | |
| Humans | |
| Influenza, Human | |
| Liver | |
| Skin | |
| Syndrome | |
| Thrombocytopenia |
Source PubMed
Cited by37
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 128 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 41958720 | A systematic review of the outcomes of desensitization for delayed-type cutaneous adverse reactions induced by antituberculosis drugs. | Asia Pac Allergy | 2026 | https://conductscience.org/library/papers/41958720 | PubMed |
| 39348373 | Efficacy of mefloquine and its enantiomers in a murine model of Mycobacterium avium infection. | PLoS One | 2024 | https://conductscience.org/library/papers/39348373 | PubMed |
| 37438379 | Real-world experience of adverse reactions-necessitated rifampicin-sparing treatment for drug-susceptible pulmonary tuberculosis. | Sci Rep | 2023 | https://conductscience.org/library/papers/37438379 | PubMed |
| 37008589 | Hepatotoxicity and tuberculosis treatment outcomes in chronic liver disease. | J Assoc Med Microbiol Infect Dis Can | 2023 | https://conductscience.org/library/papers/37008589 | PubMed |
| 34727494 | Four months of rifampicin monotherapy for latent tuberculosis infection in children. | Clin Exp Pediatr | 2022 | https://conductscience.org/library/papers/34727494 | PubMed |
| 34206314 | Rifamycin W Analogues from Amycolatopsis mediterranei S699 Δrif-orf5 Strain. | Biomolecules | 2021 | https://conductscience.org/library/papers/34206314 | PubMed |
| 32887371 | 8-Deoxy-Rifamycin Derivatives from Amycolatopsis mediterranei S699 ΔrifT Strain. | Biomolecules | 2020 | https://conductscience.org/library/papers/32887371 | PubMed |
| 31145192 | Drug hypersensitivity in HIV infection. | Curr Opin Allergy Clin Immunol | 2019 | https://conductscience.org/library/papers/31145192 | PubMed |
| 30567221 | Rifampicin: not always an innocent drug. | BMJ Case Rep | 2018 | https://conductscience.org/library/papers/30567221 | PubMed |
| 29996783 | Toxicity associated with tuberculosis chemotherapy in the REMoxTB study. | BMC Infect Dis | 2018 | https://conductscience.org/library/papers/29996783 | PubMed |
| 28671602 | Mechanism Investigation of Rifampicin-Induced Liver Injury Using Comparative Toxicoproteomics in Mice. | Int J Mol Sci | 2017 | https://conductscience.org/library/papers/28671602 | PubMed |
| 28409555 | Treatment of Latent Tuberculosis Infection. | Microbiol Spectr | 2017 | https://conductscience.org/library/papers/28409555 | PubMed |
| 27610165 | Evaluation of Hepatoprotective Effect of Silymarin Among Under Treatment Tuberculosis Patients: A Randomized Clinical Trial. | Iran J Pharm Res | 2016 | https://conductscience.org/library/papers/27610165 | PubMed |
| 27567500 | Evaluation of high-dose rifampin in patients with new, smear-positive tuberculosis (HIRIF): study protocol for a randomized controlled trial. | BMC Infect Dis | 2016 | https://conductscience.org/library/papers/27567500 | PubMed |
| 27516382 | Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis. | Clin Infect Dis | 2016 | https://conductscience.org/library/papers/27516382 | PubMed |
| 26106962 | Comparison of the safety and efficacy of a fixed-dose combination regimen and separate formulations for pulmonary tuberculosis treatment. | Clinics (Sao Paulo) | 2015 | https://conductscience.org/library/papers/26106962 | PubMed |
| 25904367 | Flu-like and Other Systemic Drug Reactions Among Persons Receiving Weekly Rifapentine Plus Isoniazid or Daily Isoniazid for Treatment of Latent Tuberculosis Infection in the PREVENT Tuberculosis Study. | Clin Infect Dis | 2015 | https://conductscience.org/library/papers/25904367 | PubMed |
| 24175948 | Hypersensitivity reactions to non beta-lactam antimicrobial agents, a statement of the WAO special committee on drug allergy. | World Allergy Organ J | 2013 | https://conductscience.org/library/papers/24175948 | PubMed |
| 20808293 | Hepatotoxic effects of therapies for tuberculosis. | Nat Rev Gastroenterol Hepatol | 2010 | https://conductscience.org/library/papers/20808293 | PubMed |
| 20546189 | Current development and future prospects in chemotherapy of tuberculosis. | Respirology | 2010 | https://conductscience.org/library/papers/20546189 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/324964
GET https://conductscience.org/api/papers/v1/324964/cited_by?page=2